2016 Agenda
Below is a detailed agenda for the Global Cardio-Oncology Summit 2016.
For your convenience, you may also print this agenda.
Thursday, September 29, 2016
7:00 am – 6:30 pm
| Time | Topic | Location / Speaker |
|---|---|---|
| 7:00 - 7:50 | Breakfast & Registration | Regency A/B/C |
| 7:50 - 8:00 | Welcome Address & Introduction | Co-Chairs: Christine Simmons, MD & Sean Virani, MD |
| 8:00 - 8:30 | Cancer and cardiovascular disease: A patient's perspective Discussion: 10 minutes | TBD |
Contemporary Breast Cancer Therapy Moderators: Susan Dent, MD & Ian Paterson, MD |
||
| 8:30 - 8:50 | Are anthracyclines relevant for breast cancer in 2016? | Chau T. Dang, MD Chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| 8:50 - 9:10 | Novel Breast Cancer Therapy: Should we have any cardiovascular concerns? | Giuseppe Curigliano, MD, PhD Medical Oncologist, European Institute of Oncology, Milan, Italy |
| 9:10 - 9:30 | Do cardiovascular preventive strategies work during chemotherapy? | Margot Davis, MD Cardiologist, Vancouver General Hospital & St. Paul's Hospital; Director, Cardio-Oncology Program, University of British Columbia, Vancouver, BC, Canada |
| 9:30 - 10:00 | Session 1 Case Review & Discussion How often should we test ejection fraction in cancer patients? | Session 1 Speakers & Case Presenter: Aarti Patel, MD |
| 10:00 - 10:15 | Break | Regency Foyer |
Thrombotic and Vascular Considerations in Patients with Cancer Moderators: Ana Barac, MD & Michael Mauro, MD |
||
| 10:15 - 10:35 | Thrombosis in Cancer Patients: Overall Considerations | Gary H. Lyman, MD, MPH Co-Director, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA |
| 10:35 - 10:55 | Biology and Pathophysiology of Vascular Effects of Cancer Therapies: How do we measure and monitor? | Kevin Croce, MD, PhD Assistant Professor of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA |
| 10:55 - 11:15 | Novel Oral Anticoagulants | Agnes Lee, MD Director, Thrombosis Program, Vancouver General Hospital, Vancouver, BC, Canada |
| 11:15 - 11:45 | Session 2 Case Review & Discussion Can thrombosis be managed in cancer patients? | Session 2 Speakers & Case Presenter: Sebastian Szmit, MD |
| 11:45 - 1:00 | Lunch | Regency D/E/F |
Keynote Debate Moderator: Jean-Bernard Durand, MD |
||
| 1:00 - 1:40 | Debate Topic: Type 1/Type 2 Cardiotoxicity: Is this nonsense? 15-minute presentation & 5-minute rebuttal each | YES: Ronald Witteles, MD NO: Juan Carlos Plana, MD |
| 1:40 - 2:10 | Session 3 Case Review & Discussion What is the aetiology of heart failure in cancer patients? | Session 3 Debaters & Case Presenter: Rupal O'Quinn, MD |
Cardiology Imaging Moderator: Negar Mousavi, MD & Jennifer Liu, MD |
||
| 2:10 - 2:25 | 2D/3D strain imaging and the role of 3D echocardiography | Dinesh Thavendiranathan, MD Cardiologist, Director, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University Health Network, Toronto, ON, Canada |
| 2:25 - 2:40 | Role of CMR in Cardio-Oncology | Mark Westwood, MD Consultant Cardiologist, Barts HEart Centre, St. Bartholomew's Hospital, West Smithfield, London, UK |
| 2:40 - 2:55 | Role of CT/CAC/Nuclear Imaging in Cardio-Oncology | Eric Harrison, MD Director of Advanced Cardiac Imaging, University of South Florida/HCA Memorial Hospital Joint Program, Tampa, FL, USA |
| 2:55 - 3:30 | Session 4 Case Review & Discussion How does imaging help the cardio-oncology patients? | Session 4 Speakers & Case Presenter: Michael Fradley, MD |
| 3:30 - 3:45 | Break | Regency Foyer |
Hematology/Oncology - Treatment Modifications to Manage Cardiovascular Toxicity Moderators: Christine Brezden-Masley, MD & Alexander Lyon, MD |
||
| 3:45 - 4:05 | Cardiac Considerations for Plasma Cell Disorders | R. Frank Cornell, MD Assistant Professor of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Centre, Nashville, TN, USA |
| 4:05 - 4:25 | Cardiovascular Toxicity in Renal Cell Carcinoma Patients | Bernie Eigl, MD Medical Oncologist, BC Cancer Agency, Vancouver, BC, Canada |
| 4:25 - 4:45 | Cardiovascular Effects of ADT in Prostate Cancer Patients | Chis J. Plummer, MD Consultant Cardiologist, Freeman Hospital, Newcastle, England |
| 4:45 - 5:15 | Session 5 Case Review & Discussion Do cardiac risk factors matter in patients with cancer? | Session 5 Speakers & Case Presenter: Jai Singh, MD |
| 5:15 - 5:20 | Closing Statements | Co-Chairs: Christine Simmons, MD & Sean Virani, MD |
Poster Reception Evaluators: Giuseppe Curigliano, MD, PhD & Margot Davis, MD |
||
| 5:20 - 6:30 | Poster Presentations Wine and Cheese Reception | |
| 6:30 | Adjourn | |
Friday, September 30, 2016
7:00 am – 4:40 pm
| Time | Topic | Location / Speaker |
|---|---|---|
| 7:00 - 7:30 | Breakfast | Regency A/B/C |
| 7:30 - 7:50 | Cardio-Oncology: Can we make a difference? | Daniel Lenihan, MD Cardiologist, Vanderbilt Heart and Vascular Center, Nashville, TN, USA |
| 7:50 - 8:10 | Vascular occlusive events with tyrosine kinase inhibitors, other agents - Who, What, Why? | Michael Mauro, MD Leader, Myeloproliferative Neoplasms Program; Attending Physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| 8:10 - 8:30 | Live Stream Discussion | Speakers |
| 8:30 - 8:40 | Opening Remarks & Day 1 Review | Co-Chairs: Christine Simmons, MD & Sean Virani, MD |
Prevention in Cardio-Oncology Moderators: Javid Moslehi, MD & Edith Pituskin, PhD, NP |
||
| 8:40 - 9:00 | Common Risk Factors Between Cancer and Cardiovascular Disease | Anne Blaes, MD, MS Associate Professor of Medicine; Program Director, Cancer Survivor Program, University of Minnesota, Minneapolis, MN, USA |
| 9:00 - 9:20 | Accelerated Cardiovascular Disease in Cancer Patients and the Cardioprotective Role of Exercise | Jessica Scott, PhD Senior Scientist, Exercise Physiology and Countermeasures, NASA Johnson Space Centre, Universities Space Research Association, Houston, TX, USA |
| 9:20 - 9:40 | Obesity is a Leading Cause of Cancer Death | Pamela Goodwin, MD Scientist, Samuel Lunenfeld Research Institute; Marvelle Koffler Chair in Breast Research, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada |
| 9:40 - 10:00 | Metabolic Issues in Cardio-Oncology | Paul Cohen, MD, PhD Albert Resnick MD, Assistant Professor, Laboratory of Molecular Metabolism, The Rockefeller University, New York, NY, USA |
| 10:00 - 10:30 | Session 7 Case Review & Discussion Can we prevent cancer progression by improving cardiac risk factors? | Session 7 Speakers & Case Presenter: Tochi Okwuosa, DO, FACC |
| 10:30 - 10:45 | Break | Regency Foyer |
Moderators: Giorgio Minotti, MD & Teresa Lopez-Fernandez, MD |
||
| 10:45 - 11:00 | Abstract #1 Discussion: 5 minutes | Kristopher Swiger, MD Nashville, TN, USA |
| 11:00 - 11:15 | Abstract #2 Discussion: 5 minutes | Trafina Jadhav, PhD, MS Nashville, TN, USA |
| 11:15 - 11:30 | Abstract #3 Discussion: 5 minutes | Helena Earl, MBBS Cambridge, Cambridgeshire, UK |
| 11:30 - 12:30 | Lunch | Regency D/E/F |
Long-Term Management in Primary Care Moderators: Barbara Fitzgerald, RN & Zaza Iakobishvili, MD, PhD |
||
| 12:30 - 12:50 | Pediatric Survivors: The transition to adult cardiovascular medicine | Lynn Straatman, MD Pediatric Palliative Care Physician, Canuck Place & BC Children's Hospital, Vancouver, BC, Canada |
| 12:50 - 1:10 | Long-Term Management: Is there a role for the cardiologist and primary care physician in the community? | Nina Ghosh, MD Director, Cancer Survivorship and Cardiovascular Disease Program, Ottawa Cardiovascular Centre, Ottawa, ON, Canada |
| 1:10 - 1:30 | Guidelines in Cardio-Oncology: Where are we now? | Saro Armenian, DO, MPH Pediatric Hematologist/ Oncologist; Associate Professor; Director, Childhood Cancer Survivorship Clinic, City of Hope Comprehensive Cancer Center, Duarte, CA |
| 1:30 - 1:50 | Role of the multidisciplinary team in cardio-oncology: bridging transitions in care | Edith Pituskin, PhD, NP Edmonton, AB, Canada |
| 1:50 - 2:20 | Session 9 Case Review & Discussion A cancer survivor in the community | Session 9 Speakers & Case Presenter: Jeffrey Sulpher, MD |
Research Frontiers in Cardio-Oncology Moderator: Javid Moslehi, MD & Laleh Amiri-Kordestani, MD |
||
| 2:20 - 2:40 | Regulatory Concerns and Pre-Clinical Testing in Cardio-Oncology | Karen Johns, MD MSc Manager/Health Products and Food Branch, Health Canada, Government of Canada, Ottawa, ON, Canada |
| 2:40 - 3:00 | NIH/NCI Partnerships and Funding Opportunities | Lori Minasian, MD Deputy Director, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA |
| 3:00 - 3:20 | Why children are at risk for cardiotoxicity | Christopher Sarosiek, PhD Instructor in Medicine, Dana-Farber Cancer Institute, Boston, MA, USA |
| 3:20 - 3:50 | Session 10 Case Review & Discussion How can science inform clinical practice in cardio-oncology? | Session 10 Speakers & Case Presenter: Brian Jensen, MD |
Future Direction Moderators: Christine Simmons, MD & Sean Virani, MD |
||
| 3:50 - 4:10 | Cardio-Oncology Fellowship Training: What does the future hold? Discussion: 5 minutes | Joseph Carver, MD Senior Administrative Officer, Abramson Family Cancer Research Institute; Director, Penn Cardiology Fellow's, Abramson Cancer Centre, Philadelphia, PA, USA |
| 4:10 - 4:30 | Opportunities for collaboration, research & education Discussion: 5 minutes | Susan Dent, MD & Daniel Lenihan, MD |
| 4:30 - 4:40 | Closing Statements | Co-Chairs: Christine Simmons, MD & Sean Virani, MD |